Drug Insights

Navigating Health Information: How to Use Synapse to Search for Diclofenac

4 February 2024
2 min read

Diclofenac Sodium, a minuscule molecule drug, wields its prowess by targeting the COX enzyme as an inhibitor. It is employed in the management of a wide range of conditions, such as bursitis, cervicobrachial syndrome, low back pain, tendinopathy, cancer pain, and osteoarthritis. First approved on August 8th, 1973, it was developed by Novartis. This multi-faceted medication combats inflammation, pain, and fever by curtailing the production of prostaglandins. Patients can take Diclofenac Sodium in a plethora of forms, including oral tablets, topical gels, and injections. The drug is undoubtedly a valuable asset for managing pain and inflammation. However, like most drugs, it can have side effects such as stomach ulcers and heightened cardiovascular risks. Due to its potential adverse effects, patients should be closely monitored by healthcare professionals before and during administration. Therefore, the use of Diclofenac Sodium should be specifically tailored to each patient's needs. Click on the image below to begin the exploration journey of Diclofenac through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

EU Commission Approves Takeda's HYQVIA® for Chronic Inflammatory Demyelinating Polyneuropathy Treatment
Latest Hotspot
3 min read
EU Commission Approves Takeda's HYQVIA® for Chronic Inflammatory Demyelinating Polyneuropathy Treatment
4 February 2024
European Commission Sanctions Takeda's HYQVIA® for Ongoing Treatment in Chronic Inflammatory Demyelinating Polyneuropathy Cases.
Read →
Unveiling the Updated Email Alert Feature in Synapse Database: A Game-changer in Data Management
Feature Updates
6 min read
Unveiling the Updated Email Alert Feature in Synapse Database: A Game-changer in Data Management
2 February 2024
The powerful intelligence alert function of the Patsnap Synapse database makes it easy for you to complete various monitoring tasks.
Read →
U.S. Fast-tracks ENHERTU® Assessment for Advanced HER2-Positive Solid Cancer Patients
Latest Hotspot
3 min read
U.S. Fast-tracks ENHERTU® Assessment for Advanced HER2-Positive Solid Cancer Patients
2 February 2024
U.S. authorities expedite assessment of ENHERTU® for individuals suffering from advanced solid cancers with HER2-positive status.
Read →
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Methylprednisolone
Drug Insights
2 min read
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Methylprednisolone
2 February 2024
Methylprednisolone is a perplexing small molecule drug that targets both the NMDA receptor as a modulator and the glucocorticoid receptor as an agonist.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.